Evidence map›Paper›PMID 33723737›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021

Bone and joint infections caused by Clostridium perfringens: a case series.

Margaux Visse, Véronique Vernet-Garnier, Odile Bajolet, Delphine Lebrun, Morgane Bonnet, Maxime Hentzien, Xavier Ohl, Saidou Diallo, Firouzé Bani-Sadr

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Margaux VisseDepartment of Internal Medicine and Infectious Diseases, Reims Teaching Hospitals, Avenue du Général Koenig, 51092, Reims, France.
Véronique Vernet-GarnierDepartment of Bacteriology, Reims Teaching Hospitals, Reims, France.
Odile BajoletDepartment of Hygiene, Reims Teaching Hospitals, Reims, France.
Delphine LebrunDepartment of Internal Medicine and Infectious Diseases, Manchester Hospital, Charleville-Mezieres, France.
Morgane BonnetDepartment of Pharmacy, Reims Teaching Hospitals, Reims, France.
Maxime HentzienDepartment of Internal Medicine and Infectious Diseases, Reims Teaching Hospitals, Avenue du Général Koenig, 51092, Reims, France.
Xavier OhlDepartment of Orthopedic Surgery, Reims Teaching Hospitals, Reims, France.
Saidou DialloDepartment of Orthopedic Surgery, Reims Teaching Hospitals, Reims, France.
Firouzé Bani-SadrDepartment of Internal Medicine and Infectious Diseases, Reims Teaching Hospitals, Avenue du Général Koenig, 51092, Reims, France. fbanisadr@chu-reims.fr.ORCID http://orcid.org/0000-0001-8268-866X
Centre Hospitalier Universitaire de Reims · FRHôpital Manchester · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to evaluate antimicrobial therapy outcomes of bone and joint infections (BJI) caused by Clostridium perfringens. We investigated remission of symptoms and the absence of relapse or reinfection during follow-up. Among the 8 patients with C. perfringens BJI, the type of infection was early prosthesis infection (n = 2), osteosynthetic device infection (n = 4), and chronic osteomyeletis (n = 2). Clindamycin-rifampicin combination was given in 4 cases and metronidazole in 4 cases. The overall success rate was 87.5%. Among the 7 patients who completed antibiotic treatment, the success rate was 100%. The clindamycin-rifampicin combination appeared to be effective in patients with C. perfringens BJI.

Indexed as

AdultAgedAged, 80 and overAnti-Bacterial AgentsBone DiseasesClindamycinClostridium InfectionsClostridium perfringensFemaleHumansJoint DiseasesMaleMicrobial Sensitivity TestsMiddle AgedRifampinAnti-Bacterial AgentsClindamycinRifampinBone infectionClindamycin-rifampicinClostridium perfringensMetronidazole

Identifiers

PMID33723737
OpenAlexW3136171080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.